Kodiak Sciences Inc.
NASDAQKodiak Sciences enters the final stretch of September with a notable divergence: most of its institutional holders remain constructive, Goldman Sachs just re-entered coverage with a cautious stance, and short sellers are quietly rebuilding positions into an 18% monthly decline. Goldman's reinstatement is the week's clearest signal shift. The firm's analyst Andrea Newkirk reinstated…
KOD put/call ratio spikes to 1.31, highest in 52 weeks—4.4 standard deviations above 20-day mean of 0.51, signaling extreme options market fear despite modest short interest declines.
Snapshot as of 26 Sept 2026
Kodiak Sciences enters the final stretch of September with a notable divergence: most of its institutional holders remain constructive, Goldman Sachs just re-entered coverage with a cautious stance, and short sellers…
Kodiak Sciences reports Q2 results on August 14 carrying one of the more charged short-interest profiles in small-cap biotech, with nearly a fifth of its free float bet against it heading into a binary data…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for KOD — free to start on ORTEX.
Sign up for free →Open KOD on ORTEX